Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Beats on EPS, Stock Up 0.48%

Ligand Pharmaceuticals reported a strong earnings per share figure, significantly exceeding expectations, which contributed to a slight increase in stock price. However, the lack of revenue data and guidance leaves some uncertainty about future performance. Investors may view the EPS beat positively, but the absence of additional financial metrics could temper enthusiasm.